FDA Calls for Further Studies for Intellipharmaceutics’ Rexista

Drug Industry Daily
A A
The FDA sent Intellipharmaceutics a complete response letter for Rexista — an extended-release oxycodone tablet rejected in July by an FDA advisory committee — calling for additional studies of the drug’s abuse-deterrent properties.

To View This Article:

Login

Subscribe To Drug Industry Daily